NorthWest Biotherapeutics Inc (NWBO)

[TTsr]

‘Major advantages of DCVax®-L include the mobilization of the entire immune system, the targeting of a full set of biomarkers on the patient’s tumor (to make it more difficult for the tumor to “escape”), the full personalization of the product to fit the patient’s own version of the tumors, and the multiplier effect of DCs mobilizing both large numbers and diverse populations of T cells. These factors are especially important in solid tumors because such tumors are so heterogeneous.’

Merck must agree with those descriptions about DCVax on solid tumors. The term “liquid biopsy” measures was mentioned. It seems like liquid biopsy can be used for biomarker analysis. Dr. Liau did adopt liquid biopsy as mentioned in one of her publications.